TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30281893

Group type: EXPERIMENTAL
Intervention: Blue-light cystoscopy with hexaminolevulinate (BLC-H)
Number of subjects: 1375

Group type: COMPARATOR
Intervention: White-light cystoscopy (WLC)
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Overall cytology
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Low-grade/WHO grade 1 disease
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: High-grade/WHO grade 3 disease
Number of subjects: 1375
Study: 28763434

Group type: COMPARATOR
Intervention: 20% mannitol (5 mL/kg infusion for 15 minutes)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (5 mL/kg infusion for 15 minutes)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline
Number of subjects: 39

Group type: COMPARATOR
Intervention: 20% mannitol
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study: 26830981

Group type: EXPERIMENTAL
Intervention: URSA Complex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24433929

Group type: EXPERIMENTAL
Intervention: Multimodal neuropsychological intervention (attention retraining, learning strategies, psychoeducation, psychological support, homework assignments) conducted once a week in 60-minute sessions for thirteen consecutive weeks
Number of subjects: 56
Study: 22492768

Group type: EXPERIMENTAL
Intervention: Detailed descriptions, CC presented first
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Detailed descriptions, IC presented first
Number of subjects: 309

Group type: COMPARATOR
Intervention: Brief descriptions, CC presented first
Number of subjects: 309

Group type: COMPARATOR
Intervention: Brief descriptions, IC presented first
Number of subjects: 309
Study: 20802056

Group type: EXPERIMENTAL
Intervention: Unilateral TAP block with ropivacaine (2.5 mg · kg(‐1) ropivacaine 0.75%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Unilateral TAP block with ropivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo TAP block (saline)
Number of subjects: 40
Study: 19166424

Group type: EXPERIMENTAL
Intervention: RLF (20 mg rabeprazole, 500 mg levofloxacin, 200 mg furazolidone once daily for 10 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RBDF (20 mg rabeprazole, 120 mg bismuth subcitrate, 100 mg doxycycline, 200 mg furazolidone twice daily for 10 days)
Number of subjects: 60
Study: 17374039

Group type: EXPERIMENTAL
Intervention: lamotrigine 25 mg QID
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: memantine 10 mg TID
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: topiramate 25 mg QID
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: diazepam 10 mg TID
Number of subjects: 127

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 127
Study: 12771706

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenously every 3 months for 1 year)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (intravenously every 3 months for 1 year)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 10698384

Group type: EXPERIMENTAL
Intervention: Milrinone, 50 microg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epinephrine, 0.03 microg/kg/min
Number of subjects: 20
Study: 9331129

Group type: EXPERIMENTAL
Intervention: Induction treatment with paclitaxel 175 to 225 mg/m2 and carboplatin (target AUC of 7.5) followed by G-CSF priming for 5 days before treatment.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combined-modality treatment (induction followed by concurrent thoracic radiation and chemotherapy).
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Induction treatment with escalated paclitaxel dose of 225 mg/m2 on days 1 and 22 after initial patients accrued.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Concurrent thoracic radiation and chemotherapy.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Concurrent thoracic radiation and chemotherapy with esophageal exposure.
Number of subjects: 35
Study: 8164452

Group type: EXPERIMENTAL
Intervention: Continuous treatment with prednimustine (60 mg daily)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Intermittent treatment with prednimustine (200 mg daily for five days every two weeks)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Continuous treatment with prednimustine
Number of subjects: 78

Group type: COMPARATOR
Intervention: Intermittent treatment with prednimustine
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 78
Study: 3746457

Group type: EXPERIMENTAL
Intervention: L-methionine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: D-methionine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: L-methionine-dl-sulfoxide
Number of subjects: 4
Study: 31725899

Group type: EXPERIMENTAL
Intervention: Single-arm trial in rare cancer disease using propensity score matching to construct an external control from RWD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized trial in children with multiple sclerosis borrowing strength from past trials using a Bayesian meta-analytic approach
Number of subjects: 0
Study: 30405294

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg PO)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 26186880

Group type: EXPERIMENTAL
Intervention: bismuth‐containing quadruple therapy (BCQT)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: bismuth‐containing levofloxacin‐based triple therapy (CBS‐LAL)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: bismuth‐containing clarithromycin‐based triple therapy (CBS‐LAC)
Number of subjects: 149
Study: 24446953

Group type: EXPERIMENTAL
Intervention: BRV 5 mg/day
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: BRV 20 mg/day
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: BRV 50 mg/day
Number of subjects: 400

Group type: COMPARATOR
Intervention: PBO
Number of subjects: 400
Study: 22397900

Group type: EXPERIMENTAL
Intervention: Robotic sacrocolpopexy (RSC)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Abdominal sacrocolpopexy (ASC)
Number of subjects: 447
Study: 20888992

Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus prednisone (25 mg/m2 cabazitaxel intravenously over 1 h every 3 weeks)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Mitoxantrone plus prednisone (12 mg/m2 mitoxantrone intravenously over 15-30 min)
Number of subjects: 755
Study: 18377099

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2,000-7,000 IU per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher doses of Vitamin D supplementation (55-70 ng per mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological doses of Vitamin D (2,000 IU per kg per day for three days)
Number of subjects: 0
Study: 15824291

Group type: EXPERIMENTAL
Intervention: Tinzaparin sodium, 175 IU/kg every 24 hours
Number of subjects: 505

Group type: COMPARATOR
Intervention: Dalteparin sodium, 200 IU/kg every 24 hours
Number of subjects: 505
Study: 12598270

Group type: EXPERIMENTAL
Intervention: Midazolam and propofol (Group M-P)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Midazolam alone (Group M)
Number of subjects: 26
Study: 10226868

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 or 8 mg once daily
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Doxazosin standard 1-8 mg once daily
Number of subjects: 707

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Doxazosin standard
Number of subjects: 707
Study: 8657211

Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 million units over one hour)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 310
Study: 1725535

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous nitroglycerin
Number of subjects: 0
Study: 7084585

Group type: EXPERIMENTAL
Intervention: Homogenised meal
Number of subjects: 5

Group type: COMPARATOR
Intervention: Solid-liquid meal
Number of subjects: 5
Study: 31722690

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention (Cool Kids), 10 sessions
Number of subjects: 228

Group type: COMPARATOR
Intervention: Usual clinical care from pediatrician
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention (Cool Kids)
Number of subjects: 228
Study: 27845956

Group type: EXPERIMENTAL
Intervention: Night-time systolic blood pressure (BP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Daytime systolic blood pressure (BP)
Number of subjects: 50
Study: 25268286

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Flexibility Training (FLEX)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of Strength and Flexibility (ST + FLEX)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of Flexibility and Strength (FLEX + ST)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 28
Study: 23106829

Group type: COMPARATOR
Intervention: Sugar (S)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Regumate (R)
Number of subjects: 92
Study: 21352389

Group type: EXPERIMENTAL
Intervention: Medication with citalopram
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Medication with reboxetine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Exclusive treatment with psychotherapy
Number of subjects: 41
Study: 18045825

Group type: EXPERIMENTAL
Intervention: WHO class IV
Number of subjects: 83

Group type: COMPARATOR
Intervention: IV‐Q
Number of subjects: 83

Group type: COMPARATOR
Intervention: WHO class III (>/=50%) and WHO‐IV
Number of subjects: 83

Group type: COMPARATOR
Intervention: ISN/RPS class IV‐S and IV‐G
Number of subjects: 83
Study: 16925808

Group type: EXPERIMENTAL
Intervention: Aspirin (81-100 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilostazol (100-200 mg/day)
Number of subjects: 0
Study: 14726734

Group type: EXPERIMENTAL
Intervention: Music intervention during rehabilitation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (without music intervention)
Number of subjects: 11
Study: 10837300

Group type: EXPERIMENTAL
Intervention: Vitamin A (7000 microg retinol equivalents as retinyl palmitate)
Number of subjects: 43559

Group type: EXPERIMENTAL
Intervention: Beta-carotene (42 mg all-trans-beta-carotene)
Number of subjects: 43559

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43559
Study: 9377905

Group type: EXPERIMENTAL
Intervention: Symptomatic intracranial haemorrhage of unknown aetiology
Number of subjects: 10
Study: 8385015

Group type: EXPERIMENTAL
Intervention: Piperacillin/amikacin/teicoplanin (group 1)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Piperacillin/amikacin/tazobactam (group 2)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 114
Study: 2871184

Group type: EXPERIMENTAL
Intervention: Relaxation therapy (16 sessions of progressive relaxation, desensitization, and EMG biofeedback)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both conditions (Relaxation and Placebo)
Number of subjects: 20
Study: 30417277

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: adalimumab 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 29724486

Group type: EXPERIMENTAL
Intervention: ePROs accessible to physicians
Number of subjects: 40

Group type: COMPARATOR
Intervention: ePROs inaccessible to physicians (Control)
Number of subjects: 40
Study: 28362949

Group type: EXPERIMENTAL
Intervention: 2 doses of influenza vaccine
Number of subjects: 499

Group type: COMPARATOR
Intervention: 1 dose of influenza vaccine
Number of subjects: 499
Study: 29340179

Group type: EXPERIMENTAL
Intervention: McKenzie Protocol (MP)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: MP and Static Endurance Exercise Group (MPSEEG)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: MP and Dynamic Endurance Exercise Group (MPDEEG)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: MP combined with Dynamic Endurance Exercise
Number of subjects: 67
Study: 24073898

Group type: EXPERIMENTAL
Intervention: e-consultation system
Number of subjects: 0
Study: 21575100

Group type: COMPARATOR
Intervention: Fentanyl 1 mcg·kg(‐1) (F1 group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl 2 mcg·kg(‐1) (F2 group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg·kg(‐1) (K group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 mcg·kg(‐1) plus Ketamine 0.5 mg·kg(‐1) (FK group)
Number of subjects: 60
Study: 18465334

Group type: EXPERIMENTAL
Intervention: Classical CMF (oral cyclophosphamide days 1-14, intravenous methotrexate and fluorouracil on days 1 and 8, repeated every 28 days)
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: Four-weekly intravenous CMF
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: Three-weekly intravenous CMF
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: Classical CMF
Number of subjects: 2213
Study: 17290563

Group type: EXPERIMENTAL
Intervention: Iron supplementation (80 mg elementary iron)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 168
Study: 12847992

Group type: EXPERIMENTAL
Intervention: 500 mg Vitamin C
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 1 g Omega-3 fatty acids
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 500 mg Vitamin C + 1 g Omega-3 fatty acids
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 68
Study: 11429120

Group type: EXPERIMENTAL
Intervention: rIFN‐gamma 0.05 mg/m(2) subcutaneously three times weekly for 48 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: rIFN‐gamma
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 9725114

Group type: EXPERIMENTAL
Intervention: Moderation training with ecological momentary assessment (EMA) using an electronic diary (ED) for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 0
Study: 7978409

Group type: COMPARATOR
Intervention: Epidural fentanyl (EF), 10 micrograms/mL in saline
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: EF with 0.1% bupivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: EF with 0.15% bupivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: EF with 0.2% bupivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 2929911

Group type: EXPERIMENTAL
Intervention: Morphine 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine 1 mg
Number of subjects: 0
Study: 28082332

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 26299230

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 4038

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4038
Study: 23810208

Group type: EXPERIMENTAL
Intervention: Bi-frontal anodal stimulation (max. current density: 0.331 mA/cm²) during early NREM sleep
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Verum tDCS
Number of subjects: 26
Study: 21213091

Group type: EXPERIMENTAL
Intervention: Usual care + ¡Viva Bien!
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 280
Study: 19925723

Group type: EXPERIMENTAL
Intervention: Loose larval therapy
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Bagged larval therapy
Number of subjects: 267

Group type: COMPARATOR
Intervention: Larval therapy (loose and bagged pooled)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Hydrogel
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Larval therapy
Number of subjects: 267
Study: 17174502

Group type: COMPARATOR
Intervention: Barium sulphate alone
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Barium sulphate + iodinated hyperosmolar contrast agent (Gastrografin)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Barium sulphate + effervescent granules (Carbex)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Barium sulphate + both iodinated hyperosmolar contrast agent and effervescent granules
Number of subjects: 149
Study: 15238971

Group type: EXPERIMENTAL
Intervention: Hypotensive anaesthesia
Number of subjects: 53

Group type: COMPARATOR
Intervention: Normotensive anaesthesia
Number of subjects: 53
Study: 11860218

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 800 microg/daily b.i.d. (n = 66)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 1000 microg/daily b.i.d. (n = 61)
Number of subjects: 127
Study: 9550512

Group type: EXPERIMENTAL
Intervention: Sensorimotor stimulation for 6 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 100
Study: 7835121

Group type: EXPERIMENTAL
Intervention: Multiload Cu250 (MLCu250)
Number of subjects: 200

Group type: COMPARATOR
Intervention: VCu200
Number of subjects: 200
Study: 30261146

Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine (9vHPV)
Number of subjects: 21

Group type: COMPARATOR
Intervention: quadrivalent HPV vaccine (qHPV)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both vaccines (9vHPV and qHPV)
Number of subjects: 21
Study: 28923786

Group type: EXPERIMENTAL
Intervention: SYNERGY
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: SYNERGY half-dose
Number of subjects: 291

Group type: COMPARATOR
Intervention: PE (PROMUS Element EES)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 291
Study: 27159854

Group type: EXPERIMENTAL
Intervention: Transnasal injection of 2 mL of 1% lidocaine + epinephrine 1:100,000 + GPC injection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transnasal injection of 2 mL of 1% lidocaine + epinephrine 1:100,000 (monotherapy)
Number of subjects: 50
Study: 23928675

Group type: EXPERIMENTAL
Intervention: Topical nepafenac
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (Systane Ultra)
Number of subjects: 120
Study: 23390832

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily
Number of subjects: 77

Group type: COMPARATOR
Intervention: Darifenacin 7.5 mg once daily
Number of subjects: 77
Study: 20733445

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system
Number of subjects: 165

Group type: COMPARATOR
Intervention: Oral medroxyprogesterone acetate
Number of subjects: 165
Study: 18215612

Group type: EXPERIMENTAL
Intervention: ximelagatran with aspirin
Number of subjects: 1883

Group type: COMPARATOR
Intervention: aspirin alone (placebo)
Number of subjects: 1883
Study: 16402749

Group type: EXPERIMENTAL
Intervention: Outward-turning wings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inward-turning wings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Figural changes that shift the center of gravity
Number of subjects: 0
Study: 12858227

Group type: EXPERIMENTAL
Intervention: 1% MNDA
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% Deet
Number of subjects: 0
Study: 10227004

Group type: EXPERIMENTAL
Intervention: 50 micrograms/day 17 beta‐estradiol for 14 weeks, combined with oral medroxyprogesterone acetate 10 mg/day during the last 2 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 14 weeks, combined with oral medroxyprogesterone acetate 10 mg/day during the last 2 weeks
Number of subjects: 40
Study: 8929263

Group type: EXPERIMENTAL
Intervention: Percutaneous radio-frequency neurotomy (multiple lesions made, electrode temperature raised to 80 degrees C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control treatment (identical procedure but radio-frequency current not turned on)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Percutaneous radio-frequency neurotomy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 24
Study: 1831505

Group type: EXPERIMENTAL
Intervention: Tetracycline (TC) fiber therapy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Scaling
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control fiber (fibers without drug)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 107
Study: 6181041

Group type: EXPERIMENTAL
Intervention: Combined treatment with intradermal administration of methanol extraction residue of BCG (MER) and split course megavoltage radiotherapy (5,000 rad over 7 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Split course megavoltage radiotherapy alone (5,000 rad over 7 weeks)
Number of subjects: 44
Study: 30089135

Group type: EXPERIMENTAL
Intervention: Galantamine 4 mg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Galantamine 8 mg
Number of subjects: 121

Group type: COMPARATOR
Intervention: Active placebo procedure
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Galantamine (both doses)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Lucid dreams compared to non-lucid dreams
Number of subjects: 121
Study: 27289121

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: Alogliptin after MI
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: Alogliptin after HHF
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: Alogliptin after stroke
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: Alogliptin after UA
Number of subjects: 5380
Study: 24903323

Group type: EXPERIMENTAL
Intervention: Football Group (FG)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Strength Training Group (ST)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control Group (CO)
Number of subjects: 26
Study: 23461218

Group type: EXPERIMENTAL
Intervention: Japanese Matrix Program (J-MAT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60